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26Polyunsaturated fatty acids are susceptible to peroxidation and they yield various degradation products, includ-
27ing themainα,β-unsaturated hydroxyalkenal, 4-hydroxy-2,3-trans-nonenal (HNE) in oxidative stress. Due to its
28high reactivity, HNE interacts with various macromolecules of the cell, and this general toxicity clearly contrib-
29utes to a wide variety of pathological conditions. In addition, growing evidence suggests a more speciﬁc function
30of HNE in electrophilic signaling as a secondmessenger of oxidative/electrophilic stress. It can induce antioxidant
31defense mechanisms to restrain its own production and to enhance the cellular protection against oxidative
32stress. Moreover, HNE-mediated signaling can largely inﬂuence the fate of the cell throughmodulatingmajor cel-
33lular processes, such as autophagy, proliferation and apoptosis. This review focuses on themolecularmechanisms
34underlying the signaling and regulatory functions of HNE. The role of HNE in the pathophysiology of cancer,
35cardiovascular and neurodegenerative diseases is also discussed.




41 1. Synthesis and breakdown of HNE
42 4-Hydroxy-2,3-trans-nonenal (4-hydroxynonenal, HNE) is an α,β-
43 unsaturated hydroxyalkenal. The molecule is highly reactive due to its
44 three functional groups: an aldehyde, a double bond (alkene) between
45 carbon C2 and C3, and a secondary alcohol at carbon C4 (Fig. 1). Carbon
46 C1 and C3 are electrophilic sites and carbon C1 is also a redox center.
47 The compound was ﬁrst described in autooxidized polyunsaturated
48 fatty acids (PUFAs) and triglycerides [1]. The ﬁrst report on the forma-
49 tion of HNE in a biological system was published Benedetti et al. in
50 Biochim. Biophys. Acta in 1980 [2]. This pioneer work investigated the
51 pathological effects of NADPH-Fe induced lipid peroxidation in liver
52microsomes, including the defective activity of glucose-6-phosphatase,
53and identiﬁed HNE as the underlying toxic intermediate.
541.1. HNE formation
55Lipid peroxidation is a general term, which refers to different mech-
56anisms and can be classiﬁed as enzymatic, non-enzymatic non-radical
57and non-enzymatic free-radical mediated peroxidation [3]. Free-
58radical non-enzymatic peroxidation of PUFAs is the dominant pathway
59in oxidative stress induced by radiation, heat, free radicals, xenobiotics,
60metal ions or reactive oxygen or nitrogen species (ROS or RNS). Hydrox-
61yl radical (OH·), themost powerful initiator of lipid peroxidation can be
62generated from hydrogen peroxide via the Fenton– and Haber–Weiss
63reactions, in the presence of free iron or copper ions. Lipid peroxidation
64can be initiated by a hydroxyl-radical-mediated removal of anH• radical
65from a lipid (LH), which yields a lipid radical (L•). In the propagation
66phase, L• reacts with oxygen and forms a lipoperoxyl radical (LOO•).
67Lipoperoxyl radical in turn reacts with another PUFA to yield a new L•
68and a lipid hydroperoxyde (LOOH). Thus, one hydroxyl radical can gen-
69erate a high number of lipid hydroperoxydes until the chain reaction is
70terminated by a chain-breaking antioxidant (e.g. tocopherol).
71Lipid hydroperoxydes are regarded as primary products of lipid per-
72oxidation (Fig. 2). However, these compounds are unstable: they can be
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F73 transformed into peroxyl and alkoxyl (LO·) radicals and can be74 decomposed to secondary products. Alkoxyl radicals are especially75 prone to β-scission, which results in the formation of short-chain prod-
76 ucts, including HNE (Fig. 2). Among the end products of lipid peroxida-
77 tion other reactive aldehydes, such asmalondialdehyde (MDA) are also
78 present; for more detailed description of the biosynthetic pathways we
79 refer to recent excellent reviews [4,5].
80 The secondary products of lipid peroxidation are reactive, yet rela-
81 tively stable compounds, they can travel remarkable distances from
82 the site of synthesis. HNE, for instance can reach well measurable
83 concentrations in the tissues and in the blood, thus it can be regarded
84 as a biomarker of the oxidative stress. Its physiological concentration
85 is in the submicromolar range (b0.1 μM), while in oxidative stress,
86 even micromolar levels can be observed [6].
87 1.2. Biotransformation of HNE
88 In situ lipid peroxidation is not the only source of HNE as it can also
89 be taken up with the food [7]. Thus, HNE is both a xeno- and an endobi-
90 otic substrate for biotransformation. Themetabolism of HNE (and other
91 secondary lipid peroxidation products) is rapid and effective, involving
92 all phases of biotransformation. Since the molecule already possesses
93 functional groups suitable for conjugation, the phases I and II of
94 biotransformation can be reversed. It should be noted that the relative
95 contribution of various pathways to HNE biotransformation markedly
96 differs in different species and tissues (see e.g.[8]), which can be in the
97 background of variable toxicity of HNE.
981.2.1. Phase I reactions
99The aldehyde group is a substrate for oxidoreductases, and it can be
100reduced to an alcoholic hydroxyl or oxidized to a carboxylic group. The
101participating enzymes are aldose reductase and aldehyde dehydroge-
102nase; they form 1,4-dihydroxynonene and 4-hydroxynonenoate,
103respectively [9,10]. The latter product can undergo a consecutive β-
104oxidation. Several cytochrome P450 isozymes have been also shown
105to catalyze both the oxidation [11] and the reduction [12] of the alde-
106hyde group. Cytochome P450s of the CYP4A family are also involved
107in the oxidativemetabolismof HNE, by catalyzing theω- andω-1 oxida-
108tion of 4-hydroxynonenoate [13,14]. Ketogenic diet upregulatesω- and
109ω-1 hydroxyation of 4-hydroxynonenoate in rat liver via the induction
110of CYP4A isozymes [14]. The hydroxyl group of carbon C4 and the
111double bond between C2 and C3 are also subjects of oxidation or reduc-
112tion, respectively.
1131.2.2. Phase II reactions
114The carbon-carbon double bond of HNE reacts with nucleophilic
115thiol groups, including that of the tripeptide glutathione (GSH). Michael
116addition leads to the formation of GSH conjugates. This spontaneous re-
117action can be highly accelerated by glutathione-S-transferases. The con-
118jugation reaction is present in most cells and tissues.
119The glutathione conjugation can be followed by oxidoreductions
120described above; and thence the glutathione conjugates of 1,4-
121dihydroxynonane and 4-hydroxynonanate are formed. Aldose reduc-
122tase has a low micromolar KM towards the glutathione conjugate of
123HNE, thus this metabolic pathways seems to be dominant in vivo [15].
124It should be noted that the glutathione conjugates of HNE are not in-
125active product, but potential signal molecules. Mitogenic effect of HNE
126has been reported to bemediated by the glutathione conjugate reduced
127by aldose reductase in rat aortic smooth muscle cells [16]. These
128compounds were also shown to mediate the inﬂammatory effect of
129oxidative or glucotoxic stress in adipocytes [17,18]. Inhibition of aldose
130reductase prevented systemic inﬂammation and cardiomyopathy upon
131endotoxin treatment [19].
132The oxidized acidic derivatives can be further metabolized by cyto-
133chrome P4504A, yieldingω-hydroxylated metabolites. Themercapturic
134acid derivatives of these products are present in the urine and can serve
135as biomarkers of in vivo lipid peroxidation (for a review see [20]). Glu-
136tathione andmercapturic acid conjugates of HNE, 1,4-dihydroxynonane
137and 4-hydroxynonanate are secreted also into the bile.
138Cysteine can be also a conjugation partner for HNE. In a recent study
139increased extracellular formation of HNE-cysteine conjugate was ob-
140served in colon cells with a mutation of the adenomatous polyposis
141coli gene; the reaction – together with the upregulation of aldehyde de-
142hydrogenases, glutathione transferase and cystine transporter – confers
143higher resistance towards HNE in mutant cells [21].
1441.2.3. Phase III reactions
145MRP1 and MRP2 multidrug resistance proteins have been shown to
146transport glutathione conjugates of HNE and to protect the cell from
147HNE toxicity [22,23]. Another ATP dependent, but non-ABC transporter,
148RLIP76 (Ral-interacting GTPase activating protein, also known as Ral-
149binding protein 1) has high transport activity towards glutathione
150conjugates of HNE; this protein accounts for the majority of the trans-
151port [24,25]. Indeed, overexpression of RLIP76 abolished the mitogenic
152effects of HNE and its glutathione conjugates observed in rat aortic
153smoothmuscle cells, while its downregulation promoted themitogenic
154effects [14].
1551.3. Adduct formation
156HNE accumulation and toxicity are counteracted by an efﬁcient and
157rapid biotransformation. Yet, in spite of these protective efforts, HNE is
158present in the cells at measurable concentrations, and gives rise to un-
159desired events. HNE is able to react readily with various cellular
Fig. 1. Chemical structure of 4-hydroxy-2,3-trans-nonenal (HNE). Circles indicate the
reactive groups of the molecule; the arrow shows the site of nucleophilic attack.
Fig. 2. Outline of HNE metabolism. HNE is generated as secondary product of lipid perox-
idation. It can be detoxiﬁed by various reactions of biotransformation; alternatively, it can
form macromolecular adducts.
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160 components, such as DNA, proteins and other molecules containing nu-
161 cleophilic thiol or amino groups [6,26]. The C2-C3 double bond is re-
162 sponsible for the Michael addition of thiol or amino compounds at the
163 C3 carbon (Fig. 3). The C1 aldehyde group can react with primary
164 amines and formof Schiff bases.While Schiff base formation is relatively
165 slow and reversible, Michael adducts are stable, thus the formation of
166 the latter is preferred in vivo. The cysteinyl, lysyl and histidyl residues
167 of proteins are the main targets of Michael addition. HNE can also
168 react with lipids containing amino groups (e.g. phosphatidyl ethanol-
169 amine, phosphatidyl serine, sphingosine) andwith nucleic acids, prefer-
170 ably with the guanin base of DNA (Fig. 3). HNE-DNA adduct formation
171 and the consequent mutagenicity occur in two independent pathways:
172 i, direct interaction of HNE with two nitrogen atoms in guanine
173 moieties,which yields four isomeric propano adducts [27], and ii, oxida-
174 tion of HNE to 2,3-epoxy-4-hydroxy-nonanal [28] and a consecutive
175 formation of exocyclic etheno adducts of guanine, adenine or cytosine
176 moieties [29,30]. The different genotoxicity of HNE in various organs –
177 beside the differences in tissue level of HNE and intensity of DNA repair
178 mechanisms – can be attributed to the tissue- or cell-speciﬁc predomi-
179 nance of one of the two pathways, e.g. the latter one is dominant in
180 hepatocytes [31]. (See Fig. 4.)Q3
181 Protein-HNE adduct formation can lead to alterations in the normal
182 functioning and modiﬁed activity of various proteins (for reviews, see
183 [32–34]. Because of its double reactivity (Michael addition and Schiff
184 bases)), HNE can contribute to protein cross-linking and induce a
185 carbonyl stress.
186 2. HNE in signaling
187 Only a few plausible effects can be outlined among the confusingly
188 pleiotropic actions of HNE in cell signaling. Antioxidant, heat shock
189 and ER stress responses are activated by HNE and these responses can
190 be integrated into a uniﬁed scheme. The three adaptive pathways
191 serve not only the disposal of HNE and the prevention of its toxic effects,
192 but also the negative regulation of proteostasis and stimulation of pro-
193 tein folding. These latter mechanisms help the cell to enter the lists
194 against adduct formation and misfolding.
1952.1. The Keap1–Nrf2–ARE pathway
196Exogenously added HNE has been shown to interact with practically
197any signalingpathways in cells (for an extensive list of these interactions
198see [35]), leading to pathological responses. These effects are due to the
199covalent interactions of HNE with key proteins of signal transduction
200pathways; there are no experimental evidences for classic, ligand-type
201interactions. Themain target of HNE as amajor endogenous electrophil-
202ic compound is the Keap1 (Kelch ECH associating protein 1)–Nrf2
203(nuclear factor erythroid 2-related factor 2)–ARE (antioxidant response
204element) pathway. This pathway senses prooxidant effects and orga-
205nizes the cellular response against oxidant or electrophile stress. The
206extremely cysteine-rich Keap1 under stress-free conditions binds Nrf2
207and directs it towards ubiquitylation and proteasomal degradation.
208Cysteine residues of Keap1 are sensitive to electrophilic attacks; while
209electrophiles in high concentrations form adducts almost completely
210with cysteinyl thiols, in low concentrations they react with a speciﬁc
211subset of thiols [36,37]. It has been reported that Keap1 directly recog-
212nizes alkenals (including HNE), NO and Zn2+ by three distinct sensors
213composed by cysteines and basic amino acids [38]. Phylogenetic analy-
214ses showed that the alkenal sensor is the most ancient one.
215Independently from the nature of the electrophilic stimuli, it seems
216that the downstream events are the same; adduct formation or oxida-
217tion of cysteine residues of Keap1 compromises its potential to recruit
218the ubiquitin ligase complex, thus Nrf2 can accumulate. The stabilized
219and accumulated Nrf2, a basic leucine zipper transcription factor, trans-
220locates to the nucleus, binds to AREs and regulates target genes. The
221proteins coded by these genes can be divided into different functional
222groups.
223NADPH generation is controlled by Nrf2 via glucose-6-phosphate
224dehydrogenase, phosphogluconate dehydrogenase, malic enzyme 1
225and isocitrate dehydrogenase 1 expression. NADPH is used by the
226glutathione and thioredoxin systems as an electron donor. The expres-
227sion of enzymes of glutathione synthesis, regeneration and utilization
228(e.g. glutamate–cysteine ligase, glutathione reductase, glutathione-S-
229transferases and glutathione peroxidase) are also regulated by Nrf2,
230similarly to those of the thioredoxin system (thioredoxin 1, thioredoxin
231reductase 1 and peroxiredoxin 1). Finally, the induction of NAD(P)H
Fig. 3. Protein and DNA adducts of HNE. Reaction between C1 aldehyde group and primary amines results in Schiff base formation (A). The C2–C3 double bond of HNE can react with
cysteinyl, lysyl and histidyl residues of proteins yielding Michael adducts (B). HNE oxidized to an epoxide reacts with different bases in DNA forming etheno adducts (C). HNE can also
form propano adducts with guanine bases of DNA (D).
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232 quinone oxidoreductase 1, heme oxygenase-1, UDP-
233 glucuronosyltransferases and multidrug-resistance associated
234 proteins completes the antioxidant effects [39]. The ﬁnal out-
235 comes of the signaling pathway are a reinforced antioxidant
236 defense and a redox shift towards the more reducing conditions.
237 Beside this simpliﬁedmechanism, Keap1 and Nrf2 are also targets of
238 protein kinases and phosphatases; many of them are also redox-
239 sensitive. Recent ﬁndings show that the PI3K pathway activates Nrf2
240 [40]. The complexity of the upstream regulation of Nrf2 is evidenced
241 by its huge interactome [41,42].
242 Recent observations suggest that the Keap1–Nrf2–ARE pathway is
243 muchmore than a signaling system for electrophilic or oxidative stress;
244 it might have a crucial function in the healthy cells too. Some of its
245 signals (e.g. NO) are produced as a second messenger upon various
246 physiological situations. Moreover, ARE-responsive proteins include
247 NADPH generating enzymes, which have prominent role in the interme-
248 diarymetabolism. These considerations raise the possibility that Keap1–
249 Nrf2 signaling plays a more general role in redox signaling [36,43].
250 2.2. Endoplasmic reticulum stress — the unfolded protein response
251 Accumulation of unfolded or misfolded proteins in the ER lumen re-
252 sults in ER stress, which provokes an adaptation mechanism called the
253 unfolded protein response (UPR). The UPR moderates protein transla-
254 tion and induces ER chaperones to restore protein folding and luminal
255 homeostasis, i.e. the normal macromolecular crowding, redox condi-
256 tions and Ca2+ concentration [44]. HNE and its effect were ﬁrstly de-
257 scribed in rat liver microsomes derived from the ER [2,45–47]; thus, it
258 is not surprising that HNE can interact with the machinery of protein
259 folding, leading to ER stress. Indeed, it has been reported thatHNE reacts
260 with the key players of ER folding, protein disulﬁde isomerase [48,49],
261 and Grp78 [48,50]. The ER stress sensor PERK kinase was activated
262upon HNE exposure in rat aortic smooth muscle cells [48]. Exogenous
263HNE provokes ER stress by a mechanism independent from ROS forma-
264tion or glutathione depletion in endothelial cells [51]. The role of ROS as
265a possible mediator of HNE-dependent ER stress was also excluded by
266another study performed in PC12 cells [52].
267An important crosstalk between the UPR and the Nrf2 pathway has
268also been described. It was observed that Nrf2 is a substrate for PERK
269ER kinase, which is activated in ER stress [53]. Upon phosphorylation
270the interaction between Keap1 and Nrf2 is weaker and the complex
271dissociates. Thus, HNE-provoked ER stress ampliﬁes the electrophilic
272signaling pathway. Interestingly, in de-differentiated cells, a constitu-
273tive (ER stress independent) PERK-Nrf2 signaling was observed, which
274protects de-differentiated cells from chemotherapy by increased anti-
275oxidant defense and drug efﬂux [54].
2762.3. The heat shock response
277Heat shock response is an adaptive mechanism, which confers resis-
278tance to various stress conditions caused by heat, electrophiles, xenobi-
279otics etc. by initiating a transcriptional program primarily regulated by
280heat shock factor 1 (HSF1). HSF1 upon stress conditions stimulates the
281expression of various heat shock proteins (HSPs). Similarly to ER chap-
282erones, their cytosolic counterparts HSP70 and HSP90 are also candi-
283dates for HNE-dependent modiﬁcations [55,56]. Although the exact
284mechanism is unknown, it can be supposed that modiﬁed HSPs lose
285their repressor functions on HSF1 activation. Thus, HNE can induce
286heat shock response by an indirect mechanism: binding to HSP70 re-
287sults in the release of HSF1 from an inactive cytosolic complex and in
288the increased transcription of the genes of heat shock proteins [33]. In
289accordance with this mechanism, HSF1 via HSP70 induction prevents
290the cell from HNE-induced apoptosis [57], while the HSP inhibitor
291geldanamycin sensitizes the cells towards HNE-dependent cell death
Fig. 4. The Keap1–Nrf2–ARE pathway of electrophilic signaling. Under basal conditions, Keap1 binds Nrf2 and promotes its ubiquitylation by Cul3 ubiquitin ligase. Upon elec-
trophilic exposure, electrophiles (e.g. HNE) react with thiol groups of Keap1, which results in the dissociation of Cul3 (Cul3 dissociation model) or in a partial detachment of
Nrf2 (hinge and latch model). In both cases Nrf2 escapes ubiquitylation, accumulates, translocates into the nucleus, binds to antioxidant response elements (AREs) and in-
creases the expression of Nrf2 target genes. Phosphorylation of Nrf2 by protein kinases (including PKC, MAPKs and the ER stress kinase PERK) also promotes the dissociation
of the Keap1–Nrf2 complex.
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292 [58]. Heat shock response activators are candidates in the therapy of
293 protein conformational diseases; many of the candidate compounds
294 are electrophiles and activators of the Nrf2 pathway too [59,60].
295 2.4. HNE signaling and proteostasis
296 Beside redox/antioxidant regulation, the Keap1–Nrf2–ARE pathway
297 is an important regulator of proteostasis. The autophagy substrate p62
298 interacts with the Nrf2-binding site on Keap1, consequently deﬁcient
299 autophagy results in the accumulation of p62, stabilization of Nrf2 and
300 transcriptional activation of Nrf2 target genes [61]. On the other hand,
301 p62 has been shown to be an ARE-responsive gene product [62], thus
302 p62 creates a positive feedback loop in Nrf2 signaling. Nrf2 dependent
303 mechanisms are also present in the crosstalk between proteasomal
304 and autophagic proteolysis. Increased autophagy was observed in mu-
305 tant mice with proteasomal dysfunction, which was stimulated by the
306 Keap1–Nrf2 pathway [63]. Nrf2 activation is required for the increased
307 level of the proteasomal regulator Pa28αβ and for maximal proteolytic
308 capacity of proteasomes [64]. Thus, electrophiles and other Nrf2 activa-
309 tors can regulate stress-induced proteasomal activity and removal of
310 damaged/misfolded proteins [65]. Since HNE-dependent ER stress and
311 the consequent activation of UPR are well documented (see above),
312 the activation of ER associated degradation (ERAD) – a proteasomal
313 pathway – and ER stress dependent autophagy is not surprising [65].
314 Moreover, HNE can also directly interact with the apparatus of transla-
315 tion; e.g. adduct formationwith eukaryotic elongation factor 2 results in
316 declined protein synthesis [66].
317 3. HNE in cell life and death decisions
318 As a potent protein-, lipid- and DNA-damaging agent, which triggers
319 ROS generation and directly depletes the antioxidant capacity of the
320 cells, HNE can be expected to cause profound changes in fundamental
321 cellular processes. Similarly to other insults, excessive lipid peroxidation
322 or HNE treatment is alsomanaged by the cells in threeways. The prima-
323 ry response aims adaptation by eliminating the damagedmolecules and
324 preventing any further aggravation and more serious consequences.
325 Cell cycle arrest (quiescence or senescence) and activation of autophagy
326 ﬁt nicely into this strategy. A short-lasting mild or moderate challenge
327 (i.e. low concentrations of HNE) can be survived this way. If the com-
328 pensatory attempts fail and the cellular intactness is in jeopardy, pro-
329 grammed cell death still provides a chance to maintain the integrity of
330 the tissue and of the whole organism. However, the energy-requiring,
331 active process of apoptosis can be accomplished only if the cell has
332 enough time and still possesses its basicmetabolic features.More severe
333 conditions, when the cell is quickly paralyzed by an overwhelming de-
334 struction (i.e. high concentrations of HNE), lead to necrosis [67] and a
335 more pronounced and expanded tissue loss usually combined with in-
336 ﬂammation. Although an increase in the level of HNE clearly reduces
337 the chance of adaptation in favor of apoptosis or necrosis, the exact
338 HNE doses determining one or the other cell response cannot be uni-
339 formly deﬁned as they vary according to the cell types, duration and
340 several environmental factors.
341 Lipid peroxidation is accelerated in oxidative stress and it is a source
342 of further ROS generation, itself. Therefore, the effects of HNE on au-
343 tophagy, cell proliferation and apoptosis are often indirect and hard to
344 distinguish from those of other ROS- and stress-activated signaling
345 mechanisms. This chapter focuses on the observations that convincingly
346 suggest a direct interaction of HNE with the key components of these
347 cellular processes.
348 3.1. Effect of HNE on autophagy
349 Besides proteasome-dependent proteolysis, autophagy is a major
350 physiologicalmechanism to degrade intracellular proteins in eukaryotic
351 cells. Autophagy plays an important role in differentiation and normal
352growth control, and its enhancement is essential for the survival during
353starvation. Macro- and microautophagy sequestrate complete regions
354of the cytosol including organelles, while in chaperone-mediated
355autophagy contributes to the cellular protein quality-control as it selec-
356tively removes damaged cytosolic proteins one by one [68]. The pro-
357teins sequestrated by autophagy are degraded in the lysosomes [69],
358and hence turn into valuable endogenous nutrient sources. Accordingly,
359the process is stimulated in energy deﬁcient states by AMP-activated
360protein kinase and inhibited during the wealth of nutrients by (insu-
361lin)-Akt-mTOR signaling [70]. The ER can also generate signals to
362enhance autophagy, in accordance to its function as a nutrient sensor
363in the cells [71]. There is ample evidence that accumulation of ROS-
364mediated damages in macromolecules and organelles plays a central
365role in aging. Elimination of damaged cellular components through
366autophagy is amajor determinant of longevity, and the repeatedly dem-
367onstrated anti-aging effect of caloric restriction can be at least partly
368attributed to an enhanced autophagic activity [72,73].
369The role of chaperone-mediated autophagy in the removal of HNE-
370modiﬁed proteinswas demonstrated in transgenicmice overexpressing
371LAMP2A receptor. The livers of these animals accumulate fewer dam-
372aged proteins compared to age-matched wild-type controls due to an
373enhanced chaperone-mediated autophagy [74]. Activation of autopha-
374gy in oxidative stress can be considered as an antioxidant defensemech-
375anism concerning the protective role it plays by eliminating damaged,
376dysfunctional proteins and organelles [75,76]. Stimulation of autophagy
377seems to be a pro-survival mechanism in cells undergoing excessive
378lipid peroxidation. HNE and other lipid peroxidation-derived aldehydes
379caused a remarkable increase in the number of autophagosomes in cul-
380tured rat aortic smooth-muscle cells. Enhanced autophagy largely con-
381tributed to the elimination of damaged proteins, and also prevented
382cell death [77]. The ER as the organelle speciﬁed to protein synthesis,
383maturation and quality control [78] is also involved in HNE-induced
384autophagy. Luminal accumulation of damaged polypeptides is the key
385trigger to the ER stress, which in turn is an important source of signals
386stimulating autophagy [79]. The contribution of the ER stress to HNE-
387enhanced autophagy was indeed demonstrated in rat aortic smooth-
388muscle cells [48]. Sublethal concentration of HNE was also shown to
389stimulate protective autophagy in differentiated SH-SY5Y neuroblasto-
390ma cells. Although caspase-3 activation was also observed in the HNE-
391treated cells, apoptotic cell death intensiﬁed only when autophagy
392had been attenuated through inhibition of glycolysis [80].
393A complex and differential regulation of autophagy by HNE during
394myocardial ischemia and reperfusion has been suggested by a recent
395study, in which the effect of endogenous HNE was attenuated by over-
396expression of aldehyde dehydrogenase 2 (ALDH2). ALDH2, one of the
397major enzymes involved in neutralization of HNE reduced the tissue
398damage in both ischemia and reperfusion; however its protective effect
399was due to promotion or inhibition of autophagy in the two phases, re-
400spectively. The results indicate that AMP-activated protein kinase and
401Akt-mTOR signaling is compromised by HNE through interference
402with upstream regulators, such as LKB1 and PTEN [81]. It can be also
403concluded that HNE-induced autophagy, albeit protective against apo-
404ptosis, has its own deleterious consequences especially in themyocardi-
405um. Suppression of HNE-stimulated autophagy in ALDH2-transfected
406mice has also been reported to ameliorate doxorubicin-induced myo-
407cardial dysfunction [82].
408Intracellular proteins severely damaged by MDA and HNE may be-
409come undegradable due to their aberrant covalent modiﬁcations and
410their deposition is potentially cytotoxic. Lipofuscin of human retinal pig-
411ment epitheliumwas shown to contain injured mitochondrial proteins,
412which indicates the role of autophagy in the formation of such granules
413[83]. Further analysis revealed that MDA and HNE interfere with lyso-
414somal protease activities in these cells both directly and through modi-
415ﬁcations of their substrate peptides [84]. The lysosomal dysfunction
416results in increased lipofuscinogenesis and reduced autophagy activity
417in vitro [85].
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418 3.2. Effect of HNE on cell cycle and proliferation
419 Protein (Ser/Thr) phosphorylations catalyzed by various cyclin:cyclin-
420 dependent kinase (CDK) dimers are key events at the checkpoints in the
421 eukaryotic cell cycle. For instance, the restrictionpoint is passedwhen ret-
422 inoblastoma protein (pRb) is hyperphosphorylated by cyclin:CDK dimers
423 accumulating as a result of mitogenic gene expression. The concomitant
424 liberation (and activation) of members of the E2F family of transcription
425 factors prepare the now committed cell to enter the S phase (DNA repli-
426 cation) [86]. CDK activities are controlled by positively andnegatively act-
427 ing phosphorylations and can be halted by the association of CDK
428 inhibitors, such as p21 or p16 [87]. The latter mechanism contributes to
429 the anti-proliferative action of p53 family transcription factors [88],
430 which in turn is activated by various stress conditions, oncogenic insult
431 and severe DNA-damage [89].
432 3.2.1. Anti-proliferative effects
433 An inverse relationship was found between cell proliferation and
434 lipid peroxidation in various cell types, i.e. it is generally observed that
435 rapid proliferation is accompanied by low level of lipid peroxidation in
436 different tissues including tumors [90]. The phenomenon is at least part-
437 ly due to low level of peroxidizable fatty acids in intensively proliferat-
438 ing cells. Enrichment with arachidonic acid renders tumor cells more
439 susceptible to oxidative stress and to cell cycle arrest through lipid per-
440 oxidation [91,92]. These ﬁndings shed light on the potential role of HNE
441 in themodulation of cell cycle control [93]. HNEwas found to reduce the
442 proliferative capacity of K562 human erythroleukemic and HL-60
443 human promyelocytic cells [94]. Not only the S phase progression was
444 inhibited, but a concomitant granulocytic differentiation was also initi-
445 ated in HNE-treated HL-60 cells [95]. Diversion from proliferation to-
446 wards differentiation implies the modulation of master regulators of
447 these processes. Indeed, the expression of proto-oncogen c-myc and c-
448 myb transcription factors is transiently suppressed in HL-60 cells after
449 HNE treatment despite unaltered N-ras expression and cAMP levels
450 [96,97]. A remarkable decrease in the c-myc mRNA level was also
451 demonstrated in K562 cells after the addition of HNE at low (1–3 μM)
452 concentration [98]. Further investigation revealed that HNE affects cell
453 cycle control around the restriction point by modifying the expression
454 of several genes. It was found to down-regulate D1, D2, and A cyclin ex-
455 pression [99], as well as to induce p21 and reduce E2F4 expression,
456 which leads to a lowered pRb phosphorylation [100]. Although p21 is
457 the major mediator of p53-induced anti-proliferative effects, its ob-
458 served HNE-dependent induction must involve other, yet-unidentiﬁed
459 transcription factors in HL-60 cells, which are known to be p53-
460 deﬁcient [101]. The profound alterations in gene expression shift the
461 ratio of DNA-bound activating “free” E2F and suppressing E2F–pRb
462 complexes towards the latter [100]. In line with these observations,
463 phenotypic transformation and immortalization was found in HLE B-3
464 and CCL-75 adherent cells upon transfection with HNE-metabolizing
465 glutathione S-transferase isozymes [102]. The complex pattern of alter-
466 ations in gene expression included the induction of TGFβ, c-myc, CDK2,
467 PKCβII and ERK1/2 as well as the down-regulation of p53, p21, p16,
468 TGFα, and c-jun [102,103]. HNE was also reported to inhibit the prolif-
469 eration of SK-N-BE neuroblastoma cells through an increased expres-
470 sion of p53 family proteins and the consequent up-regulation of p21
471 and down-regulation of cyclin D2, p53 target proteins [104].
472 3.2.2. Proliferative effects
473 It is noteworthy that positive effects of HNE on cell proliferation
474 have also been reported in a few studies. Activation of JNK (but not
475 ERK) isoforms through direct interaction by HNE leading to an increase
476 in c-jun (but not c-fos) mRNA levels and a biphasic increase in AP-1
477 DNA binding was reported in primary human hepatic stellate cells
478 [105]. In this study, these effects were related to the stimulation of
479 procollagen type I gene expression and synthesis rather than to the
480 enhancement of cell proliferation. In fact, HNE has been reported to
481reduce the platelet-derived growth factor (PDGF)-induced proliferation
482through a lowered receptor tyrosine phosphorylation in this cell type
483[106]. Stimulation of AP-1 DNA binding activity by HNE was also
484found in rat aortic smooth muscle cells. However, in these cells, some-
485what controversially, the enhanced cell growthwas attributed to the ac-
486tivation of ERK1 and ERK2 and a consequent induction of c-fos and c-jun
487protein expression [107]. The anti-proliferative effect of aldehyde dehy-
488drogenase 3A1 (ALDH3A1), an effective consumer of HNEwas shown in
489primary human corneal epithelial cells and in NCTC-2544 human
490keratinocyte cell line. However, this phenomenon might not have
491been directly related to the elimination of HNE and was more likely
492due to a signalingprotein activity of ALDH3A1 involved inmitosis rather
493than its catalytic function [108]. A striking difference between the
494effects of HNE on cell proliferation in young and old smooth muscle
495cells indicates the age-dependence and complexity of the signaling
496involved. Interestingly the increase in ERK signaling activity, cyclin D1
497expression and cell growth was more pronounced while the ROS-
498mediated cytotoxicity was less obvious in young compared to aged
499smooth muscle cells treated with low concentrations 0.1 μM of HNE
500for 36 h [109].
5013.3. HNE-induced apoptotic cell death
502Apoptosis, the major type of programmed cell death is an ATP-
503dependent and meticulously regulated process to eliminate disposable
504and/or incurable cells. The primary cause of apoptosis in physiological
505conditions is the lack of sufﬁcient survival stimuli, but it can be triggered
506also by severe stress (e.g. oxidative or organelle stress), DNA-damage,
507excessive mitogenic signal (oncogenic insult) or by stimulation of plas-
508mamembrane death receptors (e.g. FAS or TNF receptor) by exogenous
509ligands (e.g. FAS ligand or TNFα) [110]. Apoptotic caspases, central
510executors of the program, can be irreversibly activated upon limited
511proteolysis of their zymogens. Cells are protected against premature
512or inadequate caspase activation by inhibitors of apoptosis (IAPs),
513i.e. proteins blocking the active sites of caspases. Initiator procaspases
514(2, 8, 9 and 10) can be auto-activated within certain multiprotein com-
515plexes, such as apoptotosome, death inducing signaling complex or
516PIDDosome [110]. These are assembled upon the release of cytochrome
517c from the mitochondria, binding of death ligand to its receptor or p53-
518mediated gene expression, respectively. The release of pro-apoptotic
519factors from the mitochondria (e.g. cytochrome c, IAP antagonists,
520endo-DNAse) is a key event in apoptosis. The membrane pore can be
521formed by pro-apoptotic multidomain members (Bax, Bak) of the Bcl-
5222 protein family, which are normally restrained by the anti-apoptotic
523multidomain members (e.g. Bcl-2, Bcl-XL) [111]. Pore formation and
524thence apoptosis is promoted by the BH3-only members (e.g. Bad, Bid,
525Bim, Puma, Noxa) of the Bcl-2 family, which are particulate pro-
526apoptotic factors forwarding various triggers of apoptosis. Bad is kept
527phosphorylated and inactive by PKB/Akt, and initiates pore formation
528in the absence of survival signal. Bid is truncated and activated upon ex-
529ogenous death signals through the death inducing signaling complex.
530Induction of Bim is part of the ER stress response, while Puma and
531Noxa are induced by p53 [111]. The complex control of apoptosis is af-
532fected by ROS and by various reactive products of lipid peroxidation in
533multiple ways. Here we are summarizing the major mechanisms, in
534which HNE is involved directly; for a more comprehensive overview
535of the topic see Dalleau et al. [112].
536Oxidative stress affects caspase activation and function in multiple
537ways. Although the maintenance of a certain antioxidant capacity is
538required for appropriate proteolytic activity of caspases, moderate glu-
539tathione depletion seems to play an important role in procaspase cleav-
540age [113]. Two initiator (8 and 9) and the major effector (3) caspases
541were found to be activated directly by glutathione depletion in HNE
542treated human T-cell leukemia Jurkat cells. The underlying glutathione
543depletion was due to oxidation by HNE rather than Fas-mediated gluta-
544thione release across the plasma membrane [114]. HNE treatment
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545 caused oxidative stress and glutathione depletion through deregulation
546 of mitochondrial functions and induction of cytochrome P4502E1,
547 which led to an enhanced apoptosis in PC12 rat phaeochromocytoma
548 cells [115]. Stimulated expression of glutathione S-transferase A4-4, a
549 key enzyme of glutathione synthesis in these cells [115] can be consid-
550 ered as a defense mechanism since the protective effect of this enzyme
551 against HNE-induced apoptosis was revealed in human osteoarthritic
552 chondrocytes [116]. The role of glutathione depletion was further sup-
553 ported by the observation that PC12 cells can be protected from HNE-
554 induced cytotoxicity through an increased intracellular glutathione
555 level [117]. These ﬁndings do not reveal any direct interaction between
556 HNE and pro-caspase proteins, yet they strongly support the involve-
557 ment of cellular redox state-linked signaling pathways in HNE-
558 induced caspase activation. In line with this, activation of the stress ki-
559 nases JNK and p38MAPK and simultaneous down-regulation of ERK ac-
560 tivity were demonstrated to play a primary role in the HNE-dependent
561 apoptosis induction in 3 T3 mouse ﬁbroblasts [118]. The normal func-
562 tioning of the ER, especially the luminal oxidative folding is largely af-
563 fected by disturbances in the cellular redox state and it is connected to
564 glutathione homeostasis in particular [119,120]. It is therefore likely
565 that the ER stress also contributes to HNE-induced caspase activation.
566 Development of an ER stress in HNE-treated cells has been discussed
567 in relation to autophagy [48]. Several other studies support the ER
568 stressor action of HNE in various cell types [51,52] and it has also been
569 shown to be a link in HNE-induced, redox-mediated apoptosis [121].
570 In addition, the aggravation of the ER stress-induced cardiac dysfunc-
571 tion in ALDH2 knockout mice can be attributed to a similar mechanism
572 [122].
573 Interference of HNEwith the survival signal has been found in Jurkat
574 cells [123], in human osteoarthritic chondrocytes [116] and in MG63
575 human osteosarcoma cells [124]. A decrease in the amount of active
576 phosphorylated Akt, which leads to apoptosis induction thorough an in-
577 creased Bax and decreased Bcl-2 protein level, likely contributes to
578 HNE-induced cytotoxicity. However, Akt dephosphorylation and inacti-
579 vation was found to be caspase-3-dependent in HNE-treated Jurkat
580 cells, which contradicts its primary role and also strongly questions its
581 HNE speciﬁcity. It still might play a positive feedback role enhancing
582 theHNE-induced primary caspase activation. According to the proposed
583 mechanism, caspases down-regulate Src, and hence decrease the inhib-
584 itory Tyr-phophorylation of protein phosphatase 2A (PP2A), which in
585 turn dephosphorylates Akt for inactivation [123].
586 Activation of p53has beenmentioned as amechanism leading to cell
587 cycle arrest. This transcription factor is known to act as central guardian
588 of genomic integrity, and as such, it can also stimulate programmed cell
589 death after a severe damage. Accordingly, induction of p53 family gene
590 expression in HNE-treated SK-N-BE neuroblastoma cells not only hin-
591 dered proliferation but also increased the number of apoptotic cells
592 [104]. It should be noted, that p53 activation does not appear to be a
593 key factor in HNE-induced apoptosis. For example, the pro-apoptotic ef-
594 fect of HNE in RAW 264.7 murine macrophage cells has been shown to
595 be dependent on cytochrome c release but not p53 accumulation [125].
596 4. HNE in the pathogenesis of human diseases
597 Oxidative/electrophilic stress and increased lipid peroxidation are
598 important factors in the pathogenesis and progression of several
599 human diseases. Speciﬁcation of these pathologies has been the topic
600 of numerous excellent recent reviews [35,112,126]. Here we focus on
601 diseases of high incidence, inwhich the previously described alterations
602 in signaling and pathophysiology can be demonstrated.
603 4.1. HNE and myocardial diseases
604 Heart is the organ characterized by the highest oxygen uptake and
605 consumption in the body due to its constant pumping activity [127].
606 Its energy utilization mainly depends on oxidative phosphorylation by
607the myocardial mitochondria. Accordingly, the human ventricular
608myocyte contains about 7000 mitochondria, occupying approximately
60925% of the cytoplasmic volume [128,129]. The high myocardial oxida-
610tive capacity is a constant source of ROS generation and secondary
611HNE production [130]. While free radicals are short lived, HNE can per-
612sist and travel from the site of their origin [6]. Under normal conditions,
613cardiacHNE is neutralized by aldehyde dehydrogenases (ALDHs), gluta-
614thione S-transferases and aldose reductase [35,131]. However, various
615pathologic conditions, such as myocardial ischemia reperfusion, heart
616failure, doxorubicin toxicity and diabetes can overwhelm themetabolic
617capacity leading to increased HNE formation and consequential
618myocardial dysfunction [130].
619Accordinglymyocardial HNE accumulation and toxicity has been im-
620plicated in several cardiac diseases. It has been demonstrated that oxi-
621dative stress is elevated in failing human myocardium [132]. HNE-
622modiﬁed protein expressionwas5-fold elevated in patientswith dilated
623cardiomyopathy compared to controls, and carvedilol, a beta-blocker
624with intrinsic antioxidant capacity, reduced HNE levels by 40%, with
625functional amelioration of heart failure symptoms [132]. Comparison
626of 8 patients with chronic heart failure (CHF) with 8 age matched pa-
627tients revealed that patients with CHF and low ejection fraction had sig-
628niﬁcantly higher unsaturated aldehyde, including plasma HNE levels
629when compared to healthy controls [133]. Total aldehyde concentration
630was inversely correlated with +dP/dt left ventricular pressure rise, a
631well-established indicator of global left ventricular contractility, and
632cardiac output [133]. In a similar but larger scale study, the blood and
633plasma levels of protein bound HNE products (HNE-P) were assessed
634in 61 heart failure (HF) and 71 control patients [134]. All classes of cir-
635culating fatty acids and potential HNE-P precursors n − 6 PUFAs, spe-
636ciﬁcally linoleic acid were also quantiﬁed. It was shown that while the
637circulating levels of HNE-P were similar between heart failure and con-
638trol patients, HF patients had signiﬁcantly decreased levels of HNE-P
639precursor linoleic acid [134]. In addition, a strong association between
640HNE-P, linoleic acid and HDL-cholesterol was found and it was sug-
641gested that relative HNE-P increase is associated with HDL-cholesterol
642decrease in HF patients. HNE-P levels in HF patients were found to pos-
643itively correlate with New York Heart Association (NYHA) symptom
644class level [134].
645The role of HNEhas also been implicated inmyocardial ischemia and
646reperfusion injury. This assumption was tested in isolated perfused
647hearts from normotensive and spontaneously hypertensive rats with
648cardiac hypertrophy and signs of heart failure, which were subjected
649to 30 min global ischemia followed by another 30 min of reperfusion
650[135]. Generation and release of HNE were demonstrated post-
651ischemic reperfusion from myocardial efﬂuent in both animal groups.
652In addition, maximum concentration of HNE in the perfusate correlated
653with the highest incidence of ventricularﬁbrillation andmaximum con-
654tractile dysfunction in spontaneously hypertensive rats animals [135].
655The effect of ischemia reperfusion on myocardial HNE generation was
656studied in a rat heart transplantation model [136]. Excised hearts were
657ﬁrst subjected to 30, 240, 480 min of cold ischemia. Subsequently they
658were transplanted into the recipient animal, connected to the abdomi-
659nal aorta and vena cava and reperfused for 240 min. Immunohisto-
660chemical staining revealed that cold ischemia did not increase
661myocardial HNE protein adduct formation. In contrast, transplantation
662and reperfusion markedly enhanced HNE protein adduct generation
663by 6-fold, independent of preceding ischemic time [136]. Mitochondrial
664isoform aldehyde dehydrogenase 2 (ALDH2) was recently identiﬁed as
665an enzyme whose activation by phosphorylation reduced myocardial
666infarct size by 60% in a rodent model of myocardial ischemia [137]. It
667was postulated that ALDH2mediated cardioprotectionwas likelymedi-
668ated by the elimination of cytotoxic aldehydes particularly HNE. Indeed,
669pharmacologic activation of ALDH2 led to an in vitro 34% reduction of
670HNE levels and 60% in vivo reduction in infarct size [137]. The effect of
671both ALDH2 overexpression and knockout on myocardial ischemia
672and HNE protein content was further investigated [81]. ALDH2
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673 overexpression signiﬁcantly attenuated myocardial infarct size, and
674 prevented the decrease in left ventricular fractional shortening thus
675 left ventricular dysfunction following IR when compared to control an-
676 imals. In controls HNE protein adduct formation was signiﬁcantly in-
677 creased during ischemia and stayed elevated during reperfusion [81].
678 ALDH2 overexpression depressed HNE rise both during ischemia and
679 reperfusion, while ALDH2 knockout increased HNE protein adduct for-
680 mation during both circumstances. In vitro exogenous HNE treatment
681 signiﬁcantly compromised cardiomyocyte mechanical function, which
682 in turn was attenuated by ALDH2 overexpression, providing direct evi-
683 dence to HNE toxicity. The effects of chronic pharmacologic ALDH2 acti-
684 vation have been investigated recently in a post-infarction heart failure
685 rat model [138]. Male Wistar rats were subjected to myocardial infarc-
686 tion surgery via the ligation of left anterior descending artery. Heart
687 failure ensured approximately 4 weeks after coronary artery ligation,
688 at this time baseline myocardial parameters were determined, and ani-
689 malswere randomly assigned to chronic Alda-1 treatment, a pharmaco-
690 logic activator of ALDH2 enzyme. 6 weeks later the animals were
691 analyzed and sacriﬁced. Alda-1 treatment of HF animals signiﬁcantly
692 improved left ventricular ejection fraction and reversed pathological
693 ventricular remodeling of animal hearts. In the ALDH2 activated HF
694 animals HNE protein adduct levels decreased to sham operated control
695 animal levels [138]. From these experiments one can conclude, that
696 HNE accumulation plays a key role in the pathogenesis of bothmyocar-
697 dial ischemia reperfusion injury and heart failure, while its removal by
698 ALDH2 enzyme activation is a promising target for pharmaceutical
699 intervention.
700 4.2. HNE and cancer
701 Although the cytopathological effects of HNE have been discovered
702 more than three decades ago [2,139,140], the role of HNE during carci-
703 nogenesis and cancer progression is still debated.
704 Numerous HNE-induced DNA modiﬁcations were described, and
705 found to be potentially mutagenic [141–143]. The pathogenic role of
706 these DNA lesions is strongly supported by the observation that HNE-
707 DNA adducts are preferentially formed at the third base of codon 249
708 (−GAGGC/A-) in the most frequently mutated gene in human cancers,
709 the p53 [144]. Nevertheless, the greater reactivity of HNE to proteins
710 compared to DNA gave rise to the assumption that modulation of pro-
711 teins involved in DNA repair may contribute to the cytotoxic and carci-
712 nogenic effects of HNE. Indeed, HNE was shown to hinder nucleotide
713 excision repair of DNA damage induced by benzo[a]pyrene diol epoxide
714 (BPDE), as well as DNA damage induced by UV light irradiation in
715 human colon and lung epithelial cells [145]. These results strongly
716 suggest that HNE damages not only the DNA molecule itself but also
717 the DNA repair mechanisms and contributes to human carcinogenesis.
718 Initial studies found low level of HNE in tumor tissues compared
719 with healthy tissues, which was explained by rapid and efﬁcient oxida-
720 tive and conjugative pathways eliminating HNE metabolites from
721 tumor cells [146] and low rate of lipid peroxidation in hepatoma cells
722 [147]. Low levels of HNE were also associated with a decrease in the
723 synthesis and expression of the antiproliferative cytokine, transforming
724 growth factor beta1 (TGF-β1), which repression of TGFβ1 in turn has
725 been shown to correlate with an increase in carcinogenesis progression
726 in human malignant colon tumors [148,149]. Some recent studies have
727 reported controversial observations in several types of human cancers
728 [150–153]. Moreover, other results showed that HNE-protein adduct
729 formation might be implicated in different precarcinogenic stages of
730 hepatitis [154]. The discrepancy of these ﬁndings can be explained
731 with the heterogeneity of HNE formation and metabolism in various
732 tumor cells. Firstly, the membrane compositions showed different cho-
733 lesterol/polyunsaturated fatty acid ratios, which determine different
734 tendencies to HNE formation [155]. Secondly, certain tumor cells can re-
735 veal a higher expression of detoxiﬁcation enzymes and antioxidant pro-
736 teins allowing more efﬁcient and rapid HNE metabolism and excretion
737[156]. The α,β-unsaturated aldehydes produced as a result of cellular
738membrane lipid peroxidation were found to have a dose-dependent
739promoter activating effect on glutathione S-transferase, the key HNE-
740metabolizing enzyme, in rat hepatoma cells [157].
741As a cancer therapy, anticancer drugs and radiotherapy can induce
742oxidative stress and trigger cancer cells to apoptosis, however some
743cells escape the apoptosis through the adaptation to intrinsic oxidative
744stress, which confers drug resistance. The central role of Nrf2 in themet-
745abolic regulation in cancer cells were highlighted in recent studies [158,
746159]. In malignant cells Nrf2 activation provides energetic adaptability
747and growth advantage; hence increase cancer chemoresistance [160].
748Since HNE has direct inﬂuence on Keap1–Nrf2–ARE pathway, future
749studies will be necessary to distinguish physiologic and pathologic
750roles of HNE, with particular attention to the pro-oxidant anticancer
751agents and the drug-resistant mechanisms, which could be modulated
752to obtain a better response to cancer therapy.
7534.3. HNE and neurodegenerative diseases
754The sensibility of a living tissue towards oxidative stress has been
755greatly attributed to its susceptibility to lipid peroxidation, which in
756turn largely depends on its PUFA levels. While low PUFA levels can pro-
757vide an increased resistance towards oxidative stress, as in the case of
758cancer cells, certain cell types including neurons possess PUFA-rich
759membrane compartments containing high levels of the HNE-precursor
760omega-6 fatty acids. Combined with the high abundance of metal ions
761participating in redox transitions and intense oxygen consumption,
762brain tissue becomes a prime subject of free radicals and HNE-related
763degenerative disorders [161,162].
7644.3.1. Huntington's disease
765The genetic background of Huntington's disease is well deﬁned, and
766aggregation of the polyglutamine containingmutant huntingtin protein
767in the striatumand the cerebral cortex [163] has been extensively inves-
768tigated. The disease manifests as a late onset neuromotor disorder that
769has a decade long progress from increasing chorea-like involuntary
770movements to the ﬁnal stage akinesia. In exploring the pathology of
771Huntington's on the subcellular level, oxidative stress related scenarios
772have been examined. The ﬁndings, in connection with energy metabo-
773lism andmitochondrial dysfunction [164], oxidative damage in the cen-
774tral nervous system [165] and in peripheral blood [166], pointed to
775oxidative stress as a common denominator. Although the trigger has
776yet to be found, oxidative damage is generally suggested to be an impor-
777tant part of the pathophysiology of Huntington's disease. In a compre-
778hensive review by Stack et al., several oxidative modiﬁcations of
779proteins and DNA were identiﬁed, and even preventive antioxidant
780Q10 and creatine treatment was proposed [167]. Evidence of lipid per-
781oxidation was also found in Huntington's brain tissue in the form of el-
782evatedMDA and HNE levels. Furthermore, HNE was found to colocalize
783with huntingtin inclusions [168]. Inhibition of proteasomal function by
784HNE-dependent modiﬁcations [169] can lead to accelerated accumula-
785tion of aggregates. Protein degradation machinery plays an essential
786role in eliminating folding incompetent proteins. It has also been
787suggested that the decrease in superoxide dismutase levels and the
788altered energy metabolism found in Huntington's effected tissue
789samples can indirectly effect lipid peroxidation and HNE abundance
790[170].
7914.3.2. Parkinson's disease
792Most commonly known for the symptoms bradykinesia and resting
793tremors (shaking palsy), Parkinson's disease (PD) is the second most
794abundant neurodegenerative disease. PD presents with the occurrence
795of Lewy bodies found in the putamen and substantia nigra of the brain
796as the histological hallmarks of the disease. A major component of
797Lewy bodies is themitochondrial and synaptic vesicle formation related
798protein:α-synuclein (α-syn). Oxidation andnitration ofα-synhas been
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799 shown to impact aggregate formation capacity [171] while oxidative
800 modiﬁcations by ROS also impair the autophagic machinery, resulting
801 in decreased α-syn degradation [172]. Lipid peroxidation also leads to
802 the emergence of α-syn derivatives. HNE-α-syn has a greatly increased
803 oligomerization potential; consequently this adduct formation is
804 suspected to serve as a trigger for aggregation [171]. The involvement
805 of this process in the pathological progress was fortiﬁed by the ﬁnding
806 that Lewy bodies stain positive for HNE [173,174]. It has been reported
807 that different electrophiles can initiate the formation ofα-synoligomers
808 with distinct biochemical, morphological and functional proper-
809 ties [175]. It can be supposed that different oligomers affect the
810 autophagic machinery differently. HNE promotes the formation of
811 seeding-capable oligomers, which distinguished themselves by a
812 cell-to-cell transfer ability [176].
813 Besides the direct α-syn relation, HNE was also found in connection
814 with dopamine transport. The binding to the dopamine transporter and
815 inhibiting dopamine uptake further contributes to the loss of dopamine
816 dependent and dopamine secreting neurons [170,177], resulting in
817 further progression of PD.
818 4.3.3. Alzheimer's disease
819 Alzheimer's disease (AD) is the most common andmost extensively
820 studied neurodegenerative disorder with about 1000 studies published
821 annually. The relatedmental pathology frommild cognitive impairment
822 (MCI) to severe late stage Alzheimer's disease is being described in in-
823 creasing details. At the cellular level, the pathomechanism of AD is at-
824 tributed to the impaired processing of amyloid precursor protein by
825 gamma secretases leading to the accumulation of aggregation prone
826 and ROS generating amyloid beta (aβ) peptide. The broad range of stud-
827 ies approach Alzheimer's as a conformational disease [178], a neuro-
828 transmission disorder [179], a response to inﬂammatory signals [180],
829 and even a metabolic syndrome [181].
830 Increasing evidence has been collected by various groups demon-
831 strating that besides – and in connection with – the well-known senile
832 plaque pathology, increased oxidative stress is common in the central
833 nervous system in patients with AD [182,183]. Since early in vitro stud-
834 ies conﬁrmed the production of hydrogen peroxide and lipid peroxide
835 by increased aβ levels [184], the presence of various lipid peroxidation
836 products has been reported including MDA, F2-isoprostanes [182,185]
837 and HNE [186]. For the last two decades, studies have conﬁrmed the el-
838 evated HNE levels in AD, both in animal models [187] and in patients
839 [188,189]. HNE has been shown to be amember of the amyloid cascade,
840 and contributes to AD pathology as an effector for aβ-induced free
841 radicals [190–192]. The subsequent oxidative modiﬁcations affect a
842 wide variety of proteins leading to structural and functional alterations
843 in AD, both at the intracellular and synaptic membrane level [193,194],
844 including enzymes involved in the elimination of aβ itself that can even
845 lead to a disease spiral phenomenon [195]. Proteomic analysis of late
846 stage AD samples has shown that while HNE can directly affect inter-
847 neuronal communication via the modiﬁcation of key proteins such as
848 collapsin response mediator protein 2 [194] and glial glutamate trans-
849 porter (GLT-1) [196], its targets are often key enzymes of energymetab-
850 olism: aconitase, aldolase, enolase, and ATP synthase [197], as well as
851 enzymes involved in antioxidant defense: peroxiredoxins, superoxide
852 dismutase, and heme oxygenase [162]. Corollary to the dysfunction of
853 these enzymes, the defenses of neuronal tissue against oxidative
854 damage are further weakened as a result of HNE.
855 Besides the protein modiﬁcations, another reported scenario of HNE
856 causing impaired energymetabolism in AD is dihydrolipoic acid (DHLA)
857 consumption via direct adduct formation. In HNE treated brain tissue,
858 both the overall level and enzymatic activity of lipoamide dehydroge-
859 nase (LADH) was found to be decreased as a result of ROS/HNE modiﬁ-
860 cations that led to diminished DHLA production. The combined effect of
861 decreased DHLA synthesis and HNE-lipoic acid conjugate formation
862 leads to a depleted ATP pool [189].
863Due to its multiple targets and undeniable effects, lipid peroxidation
864and HNE adduct formation should attract increased attention and lead
865to further investigations in the ﬁeld of neurodegenerative disorders.
8665. Concluding remarks
867HNE emerged 34 years ago as a deleterious, cytotoxic product
868of lipid peroxidation. During the time elapsed countless pathological
869effects have been attributed to HNE toxicity. However, the intensive
870research in the ﬁeld also revealed less destructive and more speciﬁc
871effects of themolecule. Recent observations on the role of HNE in signal-
872ing have shed light on adaptive cytoprotective responses too. It became
873evident that activation of HNE sensors prepare the cells for antioxidant
874defense, stimulate the elimination of damaged cellular components or
875even serve the protection of the organism by inducing apoptosis in
876severely injured cells [112,198]. Although excessive HNE formation
877is obviously a pathogenic factor, activation of these protective mech-
878anisms deserves a great scientiﬁc interest because it might reveal
879newmolecular targets of medical signiﬁcance [36,199]. Further stud-
880ies on HNEmetabolism and signaling can contribute to the better un-
881derstanding of cardiovascular and neurodegenerative diseases.
882Moreover, HNE research can largely promote the development of
883new medical interventions, e.g. the exploration and improvement
884of electrophile therapeutics.
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